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April 6, 2010:1502–8We next investigated the gene expression in the hearts from
ntreated and treated Lmna/ and LmnaH222P/H222P female
ice, because the beneficial effect of SCH00013 was prominent
n female mice. In the hearts from untreated LmnaH222P/H222P
ice, Nppa, Nppb, Myh7, and Myl7 messenger ribonucleic acids
ere significantly increased, and the upregulation of Nppa and
yl7 was significantly reduced in the treated mice (Online Fig.
6). We also found increased messenger ribonucleic acid
xpression of proto-oncogene Fos and extracellular matrix
emodeling-related genes Tgfb1, Tgfb2, and Col1a2 in the
ntreated LmnaH222P/H222P mice, whereas these changes were
uppressed by the treatment (Online Fig. S6). Left ventricles
rom the untreated LmnaH222P/H222P mice showed 2.2-fold and
.7-fold increases of Nppa and Mlc2 proteins, respectively, as
ompared with the untreated Lmna/ mice, and the increased
xpression was suppressed by the treatment (Online Fig. S7). In
ddition, we investigated whether the apoptotic signal was
nduced by the Lmna mutation, because there is an association
mong apoptosis, cardiac myocyte drop-out, ventricular remod-
ling, and deterioration of systolic performance in various
xperimental models of heart failure. However, the number of
ransferase-mediated dUTP nick-end labeling–positive cells
as not increased in the hearts of LmnaH222P/H222P mice, and
estern blot analyses showed no or little expression of Fas-L or
as proteins, respectively, in the LmnaH222P/H222P mice (On-
ine Fig. S8). These results demonstrated that the apoptosis was
ot associated with the cardiac phenotypes in LmnaH222P/H222P
ice and suggested that loss of cardiomyocytes was caused by
ell death mechanisms other than the apoptosis.
The molecular mechanisms for the beneficial effect of
CH00013 remained unclear, but it might be related to the
hosphodiesterase III activity. This possibility is unlikely, however,
ecause SCH00013 inhibited the phosphodiesterase III activity at
uch higher concentration (IC50  64.9 mol/l) than the
oncentration at which it produced the positive inotropic effect
IC50  9.2 mol/l) in guinea pig hearts (3); and we showed that
he plasma concentration of SCH00013 in the LmnaH222P/H222P
ice ranged from 1 to 2 mol/l, although we did not measure the
oncentration in the hearts. By contrast, because the Ca2 sensi-
ivity of cardiac muscle contraction was not decreased in the
mnaH222P/H222P mice at 3 months of age (Online Fig. S9), the
a2 sensitizing effect might not play a major role at the early stage,
ut the Ca2 sensitizing effect of SCH00013 was enhanced in the
tretched muscles (5), raising a possibility that the Ca2 sensitivity in
he failed heart might be different. Although the molecular mecha-
isms should be clarified, our findings implied that the Ca2
ensitizer could be a plausible option for preventing disease progres-
ion of DCM.
akuro Arimura, DVM, PhD
ika Sato, MSc
oboru Machida, DVM, PhD
idenori Bando,
ong-Yun Zhan, PhD
achio Morimoto, PhD
yo Tanaka, DVM, PhD
oshihisa Yamane, DVM, PhD
isèle Bonne, PhD
Akinori Kimura, MD, PhD pDepartment of Molecular Pathogenesis
edical Research Institute
okyo Medical and Dental University
-5-45 Yushima, Bunkyo-ku
okyo 113-8510
apan
-mail: akitis@mri.tmd.ac.jp
doi:10.1016/j.jacc.2009.10.065
lease note: This work was supported in part by Grant-in-Aids from the Ministry of
ducation, Culture, Sports, Science and Technology, Japan; grants for Japan-France
ollaboration research and Japan-Korea collaboration research from the Japan Society
or the Promotion of Science; research grants from the Ministry of Health, Labour
nd Welfare, Japan; the Program for Promotion of Fundamental Studies in Health
ciences of the National Institute of Biomedical Innovation; and from the “Associ-
tion Francaise contre les Myopathies” (AFM) [Grant No. 11737]. We thank Dr.
asataka Hino, Zenyaku Kogyo Co., Ltd., Tokyo, Japan, for providing SCH00013
nd for measuring blood concentration of SCH00013 in mice.
EFERENCES
. Kimura A. Molecular etiology and pathogenesis of hereditary cardio-
myopathy. Circ J 2008;72 Suppl:A38–48.
. Arimura T, Helbling-Leclerc A, Massart C, et al. Mouse model
carrying H222P-Lmna mutation develops muscular dystrophy and
dilated cardiomyopathy similar to human striated muscle laminopathies.
Hum Mol Genet 2005;14:155–69.
. Endoh M, Sugawara H, Mineshima M. Pharmacology of SCH00013:
a novel Ca2 sensitizer. Cardiovasc Drug Rev 2001;19:345–66.
. Perrone SV, Kaplinsky EJ. Calcium sensitizer agents: a new class of
inotropic agents in the treatment of decompensated heart failure. Int
J Cardiol 2005;103:248–55.
. Tadano N, Morimoto S, Yoshimura A, et al. SCH00013, a novel
Ca(2) sensitizer with positive inotropic and no chronotropic action in
heart failure. J Pharmacol Sci 2005;97:53–60.
APPENDIX
or supplementary information and supplementary
gure legends, please see the online version of this article.
Letters to the Editor
Meta-Analysis of
emote Monitoring
f Heart Failure Patients
tructured disease management improves the prognosis of patients
ith chronic heart failure and has already been included in the
urrent treatment guidelines. Along with better medication and
ncreased use of defibrillators, planned periodic visits have also
ecome routine in clinical practice. Remote patient monitoring
RPM) is a different type of structured disease management.
lthough the RPM systems (telephone support, network care,
evice-assisted monitoring) and health care environments are
eterogeneous, the crucial difference from usual care is that RPM
nables daily contact with healthcare experts and thus facilitates
egular short-term evaluation of the disease status and early
ntervention. The elaborate meta-analysis by Klersy et al. (1)
ointed out considerable benefits to be gained from RPM in terms
o
n
m
t
b
s
p
w
n
a
t
i
r
t
d
c
t
*
F
*
D
C
C
D
G
E
R
1
2
3
R
W
(
t
p
a
b
n
w
a
o
o
t
b
a
s
m
A
i
c
a
a
t
f
t
f
a
t
h
c
w
s
i
u
c
v
c
t
h
1
e
i
h
i
g
s
m
m
a
r
a
1
m
f
a
i
t
i
A
*
*
B
v
P
I
E
R
1
2
1506 Correspondence JACC Vol. 55, No. 14, 2010
April 6, 2010:1502–8f mortality and hospital stay. This result is misleading. Should we
ow offer RPM to the millions of heart failure outpatients? The
ost recent trials (2,3) failed to demonstrate convincing benefits in
hese end points. What caused the discrepancy? In the era of good
aseline medication, growing defibrillator implantation rates,
cheduled visits, and good self care, it is essential to identify the
atients who might benefit from additional RPM and also those
ho will not. What are the determinants of outpatient responsive-
ess? When should RPM be used and for how long? What systems
re most suitable? What makes interventions effective? Apart from
he diversity of healthcare delivery systems requiring coordination
n each country, there might be disease-related determinants of
eceptivity to RPM. The efforts of future trials should focus on
hese aspects. The challenge is to identify patients who require
aily contact with healthcare experts as well as those who can
ontinue to receive usual care without harm. A very smart
echnology calls for very intelligent clinical implementation.
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eply
e thank Drs. Winkler and Koehler for their interest in our report
1) regarding the assessment of effect of remote patient monitoring on
he outcome of chronic heart failure patients. We appreciated their
rovocative thoughts about unmet needs in structured disease man-
gement program (e.g., identification of the patients who most likely
enefit from the technology, determinants of outpatient responsive-
ess, what makes interventions effective), which we all share; however,
e are afraid that none of these questions might have found an
nswer, given the lack of published data. As far as the differences in
utcome of 2 of the most recently published studies and the results of
ur meta-analysis are concerned, we believe that they are much less
han what Drs. Winkler and Koehler perceived.
The study by Mortara et al. (2) showed a similar outcome
etween usual care and remote monitoring (indicated in the study
s home telemonitoring). However, patients in the Mortara et al.
tudy were at least 5 to 10 years younger than those included in our
eta-analysis, and they were in a much lower New York Heart
ssociation (NYHA) functional class (ranging from 34% to 49%n NYHA functional class 3 compared with 54% [randomized
ontrolled trials] and 83% [observation cohorts] in our meta-
nalysis). Moreover, there was an unexplained imbalance, as
lready emphasized by Mortara et al., in baseline characteristic in
he large Polish cohort as indicated by a more advanced NYHA
unctional class, significantly lower left ventricular ejection frac-
ion, higher dyspnea score, and much lower sodium plasma level
or those patients assigned to home telemonitoring. A post hoc
nalysis revealed a highly significant interaction between home
elemonitoring and country in the association with the number of
ospital stays (p  0.004) and in the combined end point of
ardiac death and heart failure hospital stay (p  0.004). If one
ould put in perspective the outcome of the Italian cohort of the
tudy by Mortara et al. with the results of our meta-analysis, an
mpressive similar benefit of remote monitoring compared with
sual care would be found.
The study by Dar et al. (3) was a small, prospective, randomized
ontrolled study including 182 patients randomized to usual care
ersus home monitoring. Although the baseline demographic
haracteristics of these patients were similar to those reported in
he studies included in our meta-analysis, only 74 patients in the
ome monitoring arm and 79 patients in the usual care completed
80-day follow-up. Thus, the relative weight of the study by Dar
t al. (3) in our meta-analysis would be relatively low, and
mportantly, approximately 50% of the studies we meta-analyzed
ad a similar duration of follow-up. Of note, there were 14 deaths
n the home monitoring arm and only 4 deaths in the usual care
roup. Overall, this was an extremely high death rate for a very
hort follow-up but also impressively different between 2 treat-
ents. We were not able to find any comparative study in our
eta-analysis reporting similar death rates, which let us question
bout the reasons (not addressed in the study). Indeed, the death
ate at 12 months in all randomized controlled studies we meta-
nalyzed ranged from 14.1% (95% confidence interval [CI]: 12.8 to
5.4) to 11.7% (95% CI: 10.7 to 12.9) in the usual care and home
onitoring arm, respectively, and in observational studies it ranged
rom 13.0% (95% CI: 10.9 to 15.3) to 6.8% (95% CI: 5.3 to 8.6).
In conclusion, there is no doubt that the studies by Mortara et
l. (2) and Dar et al. (3) both represent important contributions to
mplementation of remote monitoring. Their relative weight needs
o be defined in future meta-analysis, keeping in mind some
mportant methodological issues of each study.
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